Excelsior Correspondent
SRINAGAR, July 28: Doctors Association Kashmir (DAK) today urged concerned authorities in Kashmir valley to make life-saving drug Tocilizumab available for critically-ill COVID-19 patients.
“The drug reduces the risk of death in seriously ill COVID-19 patients,” said DAK President Dr Nisar ul Hassan.
Quoting a study from the University of Michigan, he said COVID-19 patients on ventilators who received a single dose of Tocilizumab injection were 45 percent less likely to die compared to those who did not receive the drug.
“Originally developed to treat rheumatoid arthritis, the drug combats the disease by quelling cytokine storm which is the hyperimmune response of the infected person to the virus,” Dr Nisar said.
Dr Nisar said Tocilizumab suppresses the hyperimmune response by blocking receptor for a key cytokine known as interleukin-6 (IL-6) and improves survival rates and reduces mortality among Covid patients.
“Recently Indian Council of Medical Research (ICMR) in its revised protocol has allowed usage of the drug for patients with progressively increasing oxygen requirements and in mechanically ventilated patients not improving despite the use of steroids,” he said.
Dr Nisar said it is vitally important to know that there is no single magic bullet to treat the novel coronavirus and several drugs in combination are needed to tackle the virus.
“Apart from oxygen, moderate to severe patients are given steroids, remdesivir, convalescent plasma and Tocilizumab in various combinations,” he added.
Follow our WhatsApp channel